The 36-month beta value for DRMA is also noteworthy at 0.60. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for DRMA is 4.43M, and at present, short sellers hold a 2.73% of that float. The average trading volume of DRMA on May 09, 2025 was 1.53M shares.
DRMA) stock’s latest price update
Dermata Therapeutics Inc (NASDAQ: DRMA)’s stock price has gone decline by -7.12 in comparison to its previous close of 0.87, however, the company has experienced a -1.28% decrease in its stock price over the last five trading days. accessnewswire.com reported 2025-04-15 that – Dermata previously announced XYNGARI(TM) produced highly statistically significant topline data for all primary endpoints at week 12 in Phase 3 trial – – Additional data analysis revealed that XYNGARI(TM) separated from placebo after just four once-weekly treatments – – XYNGARI(TM) could be the first once-weekly topical product candidate for moderate-to-severe acne – SAN DIEGO, CA / ACCESS Newswire / April 15, 2025 / Dermata Therapeutics, Inc. (Nasdaq:DRMA)(Nasdaq:DRMAW) (“Dermata” or the “Company”), a late-stage biotechnology company focusing on the treatment of medical skin diseases and aesthetic applications, today announced that additional analysis of topline data from its Phase 3 STAR-1 trial showed that XYNGARI™ had a statistically significant difference from placebo on three efficacy endpoints as early as week 4, which occurred after just four treatments with XYNGARI™. XYNGARI™ Phase 3 STAR-1 Topline Week 4 Efficacy Results In the intent to treat analysis, Dermata saw statistically significant differences in IGA treatment success, inflammatory lesion count, and non-inflammatory lesion count at week 4 (earliest measured timepoint) when compared to placebo.
DRMA’s Market Performance
DRMA’s stock has fallen by -1.28% in the past week, with a monthly drop of -3.32% and a quarterly drop of -33.61%. The volatility ratio for the week is 10.67% while the volatility levels for the last 30 days are 11.09% for Dermata Therapeutics Inc The simple moving average for the past 20 days is 2.50% for DRMA’s stock, with a -40.79% simple moving average for the past 200 days.
DRMA Trading at -19.07% from the 50-Day Moving Average
After a stumble in the market that brought DRMA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -86.87% of loss for the given period.
Volatility was left at 11.09%, however, over the last 30 days, the volatility rate increased by 10.67%, as shares surge +0.43% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -31.93% lower at present.
During the last 5 trading sessions, DRMA fell by -1.28%, which changed the moving average for the period of 200-days by -52.35% in comparison to the 20-day moving average, which settled at $0.7902. In addition, Dermata Therapeutics Inc saw -40.00% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for DRMA
The total capital return value is set at -8.02. Equity return is now at value -310.44, with -213.46 for asset returns.
Currently, EBITDA for the company is -12.29 million with net debt to EBITDA at 0.34. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.79.
Conclusion
In summary, Dermata Therapeutics Inc (DRMA) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
